FACULTY BIOGRAPHIES

15h & 16th
October
2018

6th edition

Nice
France

Heart Failure Guidelines Forum

Better understand the Heart failure guidelines development process and its implications

GUIDELINES FORUM by TMA HFGF

TMA TRANSLATIONAL MEDICINE ACADEMY

CONTENTS

Clinical practice guidelines and associated implementation strategies are essential to promote optimal, evidence-based practices in heart failure prevention and management. While current practice guidelines are generally in agreement, specific recommendations may differ, reflecting diverging interpretations of the available evidence or the lack of sufficient data to make evidence-based recommendations. In addition, a number of questions arise as a result of a rapidly changing clinical landscape and attempts at addressing unmet clinical needs.

The Guidelines Forum on Heart Failure aims to gather a multidisciplinary panel of leading academic international experts and industry representatives involved in basic and clinical research to discuss the latest evidence, ongoing research and controversial issues that have implications for clinical practice.

Chairs 3

Faculty Members 7

EMA representatives 25

Guidelines Forum

CHAIRS

Stefan D. Anker

MD, PhD, FESC
Contact: Charité Campus CVK, Division of Cardiology & Metabolism, Dept of Cardiology & BCRT, Augustenburger Platz 1, D-13353 Berlin, Germany.

Stefan D. Anker is *Professor of (Tissue)Homeostasis in Cardiology & Metabolism* (W3) at Charité Berlin (from June 2017). Dr. Anker studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his M.D. from Charité Medical School, Berlin, Germany (1993), and his Ph.D. (1998) at National Heart & Lung Institute of Imperial College London. He was *Professor of Cardiology & Cachexia Research* (W2) at Charité (2002-14), and *Professor of Innovative Clinical Trials* (W3) in Göttingen (2014-17).

Dr. Anker has authored more than 800 original papers, reviews, and editorials that are well cited. For his work Dr. Anker has won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. He obtained a number of fellowships & grants, incl. 2 from NIH (WARCEF EU), 2 EU-FP7 & 2 IMI/Horizon2020 grants. He was co-ordinator for "SICA-HF" (EU-FP7). He received grants for three IITs that are currently running for >13 Mill EUR (from DZHK Germany & several industries).

Dr. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board 2012-2018. Dr. Anker serves in the board of the Heart Failure Association (HFA) of the ESC since 2006; he was HFA President (2012-14). He is founding Editor-in-Chief of the open access journal *ESC Heart Failure*. Dr. Anker worked in several ESC Guideline task forces (e.g. the ESC HF guidelines 2012 & 2016). Dr. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD – see www.cachexia.org). Dr. Anker is founding Editor-in-Chief of the *Journal of Cachexia, Sarcopenia and Muscle* (JCSM, 2016-IF: 12.51, see www.jcsm.info). Dr. Anker was and is member of >30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, EMPEROR-HFpEF, Fair-HFpEF, EMPERIAL-HFpEF, RELIEVE-HF) as well as in the past (incl. FAIR-HF, TIM-HF, AUGMENT-HF, IMPULSE-HF & BACH). He served in a number of DMC's (chairing 4) and end-point committees (chairing 4).

Gerasimos Filippatos

Dean, School of Medicine
University of Cyprus
Professor of Cardiology, University of Cyprus &
National and Kapodistrian University of Athens

Gerasimos Filippatos studied Medicine at the University of Patras, GR, and earned his doctorate Cum Laude from the University of Athens. He subsequently completed his clinical training in Chicago, USA; and Cambridge, UK.

Prof Filippatos is past President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). He has served as Chair of the Clinical Section and the Committee on Acute Heart Failure of the HFA, and as Chair of the ESC's Working Group on Acute Cardiac Care. He was also Coordinator of the ESC Congress Programme Committee for Heart Failure and Acute Cardiac Care, member of the ESC Practice Guidelines Committee and American College of Cardiology/American Heart Association HF Guidelines Writing Committee, and International Governor of the American College of Chest Physicians.

Dr. Filippatos is Associate Editor of the European Heart Journal (impact factor>20), the International Journal of Cardiology and of the Journal of Cardiovascular Medicine. He has published over 450 articles in peer-reviewed journals and authored more than 30 book chapters including the "Acute Heart Failure" chapter in Braunwald's and Oxford Desc Reference: Cardiology. Moreover, he has (co) edited 5 books including the ESC Textbook of Acute and Intensive Cardiac Care, Highly Commended in the 2011 British Medical Association Medical Book Awards; in 2014 presented the book Heart Failure: The Expert's Approach and in 2016 the pocket book: Treatment Algorithms in Heart Failure.

Prof. Filippatos is in the Thomson Reuters list of Highly Cited Researchers.

Honorary Member of many Cardiac Societies: ie French Cardiac Society, Romanian Cardiac Society, Hungarian Cardiac Society.

Petar M. Seferovic

President, Heart failure Association of the ESC
Corresponding member of Serbian Academy of Sciences and Arts
Professor, University of Belgrade Faculty of Medicine and
Heart Failure Center, University Medical Center, Belgrade
President, Heart Failure Society of Serbia

Petar Seferovic is President of the Heart Failure Association of the European Society of Cardiology.

He has a long standing experience in the activities of ESC, and later was involved in Heart Failure Association projects for almost a decade.

He is a Chair of Internal medicine, Belgrade University School of Medicine and Professor, Heart failure Department, University Medical Center Belgrade, Belgrade, Serbia. After completing his training and fellowship at Belgrade University School of Medicine and Kings College Hospital in London, UK, he spent two years as a Visiting Assistant professor in Methodist Hospital and Baylor College of Medicine, Houston, USA. Prof. Seferovic was leading the introduction of several methods of interventional cardiology and myocardial and pericardial disease in Serbia, including percutaneous transluminal angioplasty, endomyocardial biopsy, percutaneous pericardioscopy and pericardial biopsy. Starting mid-90's, he dedicated his clinical and research activity to chronic and acute heart failure. He is Corresponding member of Serbian Academy of Sciencies and Arts and President, Heart Failure Society of Serbia

His research interests mainly include heart failure, acute and chronic, cardiomyop thies, myocarditis, pericardial disease as well as cardiovascular disease and diabetes. He has been involved in numerous heart failure clinical trials as a National coordinator and Principal investigator, member of international steering committees, endpoint committees, and advisory boards.

Prof. Seferovic has coauthored a total of 570 publications, with cumulative impact factor of 730 (h-index 31), including multiple papers in peer-reviewed international journals. He has a total citation of 15560 (Google Scholar) / 14758 (Scopus). He presented more than 221 lectures at International conferences.

He acted as a Task Force member on several ESC guidelines, including ESC guidelines on the diagnosis and treatment of acute and chronic heart failure, the ESC guidelines for the management of pericardial disease, and the guidelines on cardiovascular diseases in diabetes. In addition, Petar Seferovic serves as a reviewer for several journals.



Guidelines Forum

FACULTY

William T. Abraham

M.D., F.A.C.P., F.A.C.C., F.A.H.A., F.E.S.C., F.R.C.P.
Professor of Internal Medicine, Physiology and Cell Biology
Chair of Excellence in Cardiovascular Medicine
Associate Dean for Clinical Research
Chief, Division of Cardiovascular Medicine
Medical Director, Clinical Trials Management Office
Deputy Director, Dorothy M. Davis Heart and Lung Research Institute
The Ohio State University, Columbus, Ohio

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center. He previously held leadership positions at the University of Colorado, the University of Cincinnati, and the University of Kentucky. At the Ohio State University, Dr. Abraham holds several leadership positions including an Associate Dean position, managing the College of Medicine's non-cancer clinical and translational research portfolio. As Division Director, Dr. Abraham has developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.

Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology. He spends the majority of his clinical time managing heart failure patients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the "Best Doctors in America" for sixteen consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction.

Dr. Abraham's research program focuses on elucidating basic mechanisms in heart failure and on clinical drug and device trials in heart failure. Dr. Abraham has received grants from the National Institutes of Health (NIH) including current NIH funding totaling more than $18 million, the American College of Cardiology, and the Aetna Quality Care Foundation. He has made major contributions to advancing clinical science and patient care in heart failure in at least three areas: device development in heart failure; neurohormonal therapies in heart failure including beta-blockers, natriuretic peptides, and vasopressin receptor antagonists; and acute heart failure and renal dysfunction complicating heart failure. His work has contributed to the approval and adoption of several therapies for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration devices, implantable hemodynamic monitoring devices, and transvenous phrenic nerve stimulation.Dr. Abraham has authored more than 1,000 original papers, abstracts, book chapters, and review articles. His work has been published in high impact journals, including The New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation, the European Heart Journal, and the Journal of the American College of Cardiology. Dr. Abraham has co-authored national heart failure practice guidelines and co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment and serves as series editor for the Color Atlas and Synopsis of Cardiovascular Medicine. Dr. Abraham serves on the editorial boards of several major journals. From 2014 through 2018, he was named to the Clarivate Analytics (formerly Thomson Reuters) Highly Cited Researchers list and as one of The World's Most Influential Scientific Minds. In 2017, he received the Distinguished Scientist Award (Clinical Domain) from the American College of Cardiology.

Javed Butler

MD, MPH, MBA

Javed Butler is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.

He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.

Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Dr. Butler has authored more than 500 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America's Best Doctors list.

John G. F. Cleland

MD, PhD, FRCP, FACC, FESC.
John.cleland@glasgow.ac.uk / j.cleland@imperial.ac.uk

Professor Cleland was appointed the Director of the Robertson Centre for Biostatistics and Clinical Trials in 2016, an internationally accredited Clinical Trials Unit offering a complete service both to academic clinicians and industry. The special area of expertise is cardiovascular disease but includes all branches of medicine and social sciences.

He qualified from the University of Glasgow and completed his training at St. Mary's, Paddington and Hammersmith Hospitals, London in 1989. In 1994, he was awarded a Senior Fellowship by the British Heart Foundation, moving back to Glasgow. He was appointed Professor of Cardiology at the University of Hull in 1999 and subsequently, in 2013, at the National Heart & Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College London, where he retains a part-time contract.

His main area of interest is in heart failure, extending from its epidemiology and prevention, to Phase II-IV randomized trials through to the development and implementation of guidelines. Particular current interests include the influence of myocardial substrate on therapeutic response, congestion and inflammation as novel therapeutic targets, telemonitoring and theranostics.

He is a Past Chairman of the ESC Working Group on Heart Failure and of the British Society for Heart Failure, founded the European Journal of Heart Failure and chairs the Academic Committee of the National Heart Failure Audit and the National Clinical Specialties Research group on Heart Failure. He has published more than 800 papers in peer reviewed journals and is a Thomson Reuters Highly Cited Researcher.

Andrew Coats

Andrew was born in Melbourne, Australia and studied Medicine at Oxford and Cambridge. He has published over 20 patents and more than over 600 peer-reviewed research papers. He has more than 75,000 career citations, and a personal H-index of 121. He served as Editor-in-Chief of the International Journal of Cardiology from1999 to 2016 and has served on more than 10 major journal editorial boards. Andrew is an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggerated ventilatory responses in CHF patients. He first described chemoreflex overactivity in CHF and periodic breathing and published the first ever randomised trial of exercise training for CHF.

Andrew has been Chairman or Committee member of the following major Cardiovascular and Cancer Cachexia Clinical Trials: CHRISTMAS, CHARM, COPERNICUS, OXAM, OPTIMAAL, OVERTURE, REPLACE, SENIORS, AUGMENT-HF and ACT-ONE. He has served Head of Cardiology at Imperial College and Director of Cardiology at Royal Brompton Hospital, London then as Dean of Medicine and Deputy Vice-President at the University of Sydney, and as Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. He is presently President Elect of the Heart Failure Association of the ESC.

Kenneth Dickstein

MD, PhD FESC
University of Bergen, Stavanger University Hospital,
Stavanger, Norway.

Kenneth Dickstein was born in Philadelphia and completed undergraduate education at the Univ. of Pennsylvania. He has medical degrees from the Univ. of London and the Royal College of Surgeons in Dublin. He was a research fellow at Harvard Medical School (1988-90) and completed his PhD in exercise physiology at the Univ. of Bergen in 1992. Professor Dickstein was in charge of the coronary care unit at Stavanger University Hospital, full professor of medicine at the Univ. of Bergen and was coordinator for the medical student teaching program at the hospital. His primary focus is clinical research in heart failure with an interest in both pharmacologic therapy and the use of cardiac devices in patients with heart failure.

Professor Dickstein is a Past-President of the Heart Failure Association of the European Society of Cardiology and has been a councillor on the ESC Board. He was Chairman of the Task Forces for two of the ESC Guidelines on Heart Failure. In 2016, he received the National Research Prize from the Norwegian National Society and the Falch Research Prize from the University of Bergen in 2017. Prof. Dickstein has been an author on over 370 scientific papers and held over 400 invited lectures at international venues. He is the founder of the ESC patient website heartfailurematters.org, is a member of numerous editorial boards and steering committees and is an active associate editor of the European Journal of Heart Failure. He resides with his wife and 2 sons on the west coast of Norway and spends his summers fly fishing.

Gerd Hasenfuß

Gerd Hasenfuß is Professor of Internal Medicine and Cardiology and is Chair of the Clinic of Cardiology and Pneumology at University Medical Center Göttingen (from April 1998) and Chair of Heart Center Göttingen, and of HRCG.

Dr. Hasenfuß received his training in medicine at University of Freiburg from 1982 to 1988. From 1988 to 1990 he was Visiting Assistant Professor at Department Molecular Physiology and Biophysics, University of Burlington, Vermont, USA. 1993 to 1998 he was an Assistant Professor in Internal Medicine and Cardiology, University of Freiburg. He is also Chief of Clinics and Rehabilitation Center Lippoldsberg since 2005. Since 2011 he is member of the Board of Directors of the DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V.), and since 2012 Speaker of the SFB 1002, CRC (Collaborative Research Center) «Modulatory Units in Heart Failure».

In 2013, he joined the Board of Directors of DGIM (Deutsche Gesellschaft für Innere Medizin e.V.). Dr. Hasenfuß has authored 495 original papers, reviews, and editorials (h-index: 72). Dr. Hasenfuß has won several prizes and obtained a number of fellowships, awards and honours. He has been a Principal Investigator of several clinical trials.

His main research interests are heart failure pathophysiology and clinical treatment, calcium cycling, electrophysiology, and stem cell biology.

Friedrich Koehler

© Peitz/Charité Universitätsmedizin Berlin.

MD, FESC is Senior Physician in Cardiology at the Medical Department, Division of Cardiology and Angiology, Charité - Universitätsmedizin Berlin and Professor for Cardiovascular Telemedicine.

He is Head of the Centre for Cardiovascular Telemedicine which is the specialized in research and development projects of remote patient management of heart failure patients. From 2013-2018 he was Principial Investigator of the public funded randomized controlled trial «Telemedical Interventional Management in Heart Failure II» (TIM-HF2, NCT01878630) with 1,538 heart failure patients. Also, he is working in task forces for Digital Medicine in the European Society of Cardiology and German Society for Internal Medicine (DGIM).

Mitja Lainscak

Dr. Mitja Lainscak is Professor at Faculty of Medicine, University of Ljubljana and does clinical practice & research at Division of Cardiology, General Hospital Murska Sobota, Slovenia. His clinical and research interest is cardiovascular medicine with particular emphasis on heart failure, pharmacotherapy, and metabolism with body composition. Currently he holds an Executive Committee member position at the Heart Failure Association of the ESC, and is a Fellow of the HFA and of the ESC. In 2018, he was the Scientific Chairperson of the Heart Failure Association annual congress. Professor Lainscak has published more than 200 papers and contributed to several book chapters. He is Associate Editor at Journal of Cachexia, Sarcopenia, and Muscle and ESC Heart Failure.

Theresa A. McDonagh

MD, FRCP, FESC.
Consultant Cardiologist, and Clinical Lead for Cardiology and Heart Failure
King's College Hospital Denmark Hill London, SE5 9RS Tel:020 3299 3259
Email: theresa.mcdonagh@kcl.ac.uk

Professor McDonagh qualified from the University of Edinburgh and completed her internal medicine training there. She trained in Cardiology at the Western Infirmary in Glasgow. Her main research was on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides hormones.

Subsequently she was appointed as a Senior Lecturer at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). Following this she was a Consultant Cardiologist at the Royal Brompton Hospital, London (2004-2011) where led the Heart Failure Service, before moving to King's College Hospital to head up the Heart Failure Programme.

Her main research interests are in novel biomarkers for heart failure and the delivery of heart failure services.

She is a past Chair of the British Society for Heart Failure a Past Chair of the Clinical Section of the Heart Failure Association of the European Society of Cardiology. She is the Clinical Lead for the National Heart Failure Audit.

Marco Metra

University of Brescia, Italy

Marco Metra is Professor of Cardiology and Director of the Institute of Cardiology of the Department of Medical and Surgical Specialties, Radiological Sciences and Public Health of the University and Civil Hospitals of Brescia, Italy.

He is Editor-in-Chief of the European Journal of Heart Failure, the official journal of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Senior Consulting Editor of the European Heart Journal and member of the Editorial board of many other scientific journals. His research activity is focused on treatment of heart failure and its comorbidities. He has had a leading role in multiple trials of new therapies in patients with heart failure.

He is the ex-officio member of the board of HFA, a fellow of HFA, ESC, the Heart Failure Society of America, a member of the Italian Society of Cardiology (SIC) and many other scientific societies.

He is author of more than 500 articles in peer-reviewed journals with a current google scholar H index of 86.

Martin Möckel

Prof. Dr. Martin Möckel, FESC, FAHA
Charité-Universitätsmedizin Berlin, Germany

Martin Möckel is a Senior Physician, Professor of Cardiology and Head of Emergency Medicine and Acute Cardiovascular Care at Charité-Universitätsmedizin Berlin, Germany. His research focuses on biomarkers, health care research in Emergency and Acute Medicine, the application of interventional therapy in acute coronary care and he has led a number of multicentre trials. He is an Adjunct Professor at the James Cook University, School of Public Health and Epidemiology, Townsville, Australia. Professor Möckel is joint Head of the Medical Apps Group for the German Cardiac Society. He is also a Fellow of the European Society of Cardiology, and an International Fellow of the American Heart Association.

Professor Möckel has delivered more than 200 oral and poster presentations at leading national and international conferences and has published extensively in the fields of emergency medicine, acute cardiac care and health care research. He is part of the biomarker core groups of the Acute Cardiovascular Care Association and the upcoming congress president 2019 of the German Society for Internal Intensive Care and Emergency Medicine.

Georg Nickenig

MD
Germany
Professor of Internal Medicine/Cardiology
Direktor of the Medical Clinic II, - Internal medicine, Cardiology, Angiology, Pneumology and Intensive Care
University Clinic
Bonn

Prof. Georg Nickenig has studied medicine at Rheinischen Friedrich-Wilhelms-University in Bonn. After residency at the Medical University Polyclinic in Bonn, he spent two years with research grant in Emory University Medical School, Department of cardiology/Pharmacology in Atlanta, USA. From 2000 to 2005, after working at the Cardiology Department of the University Hospital in Cologne, he was working as Professor of Cardiology in the Department of Internal Medicine III (Cardiology) at the University Hospital of the Saarland in Homburg.

In 2005 he was appointed to the Chair of Internal Medicine, Division of Cardiology and Pneumology at the University of Bonn and as Director of Medical Hospital II at the University Hospital Bonn.

The focus of the work of Georg Nickenig are coronary heart disease, heart failure and atrial fibrillation. Research focuses on molecular and cellular mechanisms of atherosclerosis and aortic disease and clinical research on coronary structural heart disease.

He has authored or co-authored more than 500 articles in international peer-reviewed journals.

Jean-François Obadia

Professor Jean-François Obadia is actually the chief of a department of Adult Cardiac surgery in Lyon – France. As a member of EACTS, ISHLT, AATS, he is mainly involved in valvular Surgery and Cardiac assistance and transplantation.

The valvular program includes all aspects of valvular surgery from the most complex repairs for endocarditis (Homograft of monobloc aorto-mitral) to the minimally invasive approaches for mitral. The surgeons are involved with a strong input in the developpement of the per-cutaneous approaches for the aortic valves (TAVI) and Mitral vales (Mitraclip, Valve in Valve, Valve in MAC, Neochord, Tendyne...). He was the PI of the Mitra.fr study recently published in the NEJM.

The transplantation program includes 45 hearts transplantations, 15 Mono Left assistance, 15 bi-VAD and around 100 ECMO.

Ileana L. Piña

MD, MPH
Professor of Medicine
Professor of Epidemiology & Population Health
Albert Einstein College of Medicine
Associate Chief for Academic Affairs
Montefiore Medical Center Heart and Vascular
Bronx, New York

Ileana L. Piña, MD, MPH, is a Professor of Medicine, Epidemiology & Population Health at the Albert Einstein College of Medicine and Associate Chief for Academic Affairs at Montefiore Medical Center in the Bronx, New York. Dr. Piña also serves as advisor/consultant to the Food and Drug Administrations' Center for Devices and Radiological Health and their section of Epidemiology.

Dr. Piña earned her undergraduate degree in chemistry from the University of Miami in Florida. She completed her medical degree and cardiology fellowship at the University of Miami School of Medicine; an internal medicine residency at the University of South Florida Tampa, where she was Chief Resident; and fulfilled a surgery internship at the University of Miami Hospitals and Clinics. She earned a master's degree in public health from Case Western Reserve University School of Medicine in Cleveland, Ohio while pursuing a VA Quality Fellowship.

Dr. Piña's research interests include transition of care in heart failure patients, and the role of natriuretic peptide–guided management for patients hospitalized for heart failure, biomarkers of myocardial stress and fibrosis in chronic heart failure, and heart failure differences by sex. She is the author/co-author of more than 100 publications.

Piotr Ponikowski

Piotr Ponikowski is professor of cardiology and Head of the Department of Heart Diseases at the Wroclaw Medical University in Poland. He is also Head of the Department of Cardiology at the Centre for Heart Diseases at the 4th Military Clinical Hospital, Wroclaw, Poland. At the Wroclaw Medical University, he currently serves as the Vice-rector for scientific affairs.

Professor Ponikowski is the President of the Polish Cardiac Society, he served as the President of the Heart Failure Association of the European Society of Cardiology (2010-2012) and was a Councilor of the European Society of Cardiology board (2012-2014). He has been involved in the development of several ESC guidelines as the member of the ESC Committee for Practice Guidelines and was the Chair of the 2016 ESC Heart Failure Guidelines. He is also a guest editor and member of the editorial board for several cardiology-focused journals.

Professor Ponikowski serves as an advisor and consultant for a range of pharmaceutical companies and has been a member of international steering/executive committees and endpoint committees of numerous clinical trials.

His research interests focus on the pathophysiology and management of acute and chronic heart failure, and recently particularly on the aspects of iron deficiency and reflex control in the cardiorespiratory system. He has co-authored over 600 publications and has more than 44000 citations in international literature.

Prof. Lynn W. Stevenson

Dr. Stevenson has been Director of Cardiomyopathy and Heart Failure Programs at UCLA, Brigham and Women's Hospital, and has recently moved to become Director of Cardiomyopathy and the Lisa Jacobson Professor of Medicine at Vanderbilt University. She has been an active member of AHA, ACC, ISHLT, and HFSA societies and a major contributing writer to 30 national guidelines relating to heart failure, cardiac transplantation, ventricular assist devices, arrhythmia devices, and decision-making in advanced heart failure.

For the past 30 years she has supervised training of 50 fellows in heart failure and transplantation, over half of whom over are women and almost all are currently in academic positions in heart failure and transplantation.

She has served on the FDA cardio-renal panel and the MEDCAC advisory panel and participated over many years in the national accreditation of heart transplant and VAD programs. She has played leadership roles in NHLBI-sponsored studies for strategies of medical and device therapies in advanced heart failure, was one of the designers of the INTERMACS and NCDR ICD registries, collaborates with the Cardio-Thoracic Surgery Network and has mentored 2 networks of NHLBI young investigators.

Her academic work reflects multiple aspects of heart failure physiology and clinical assessment focusing on taking the congestion out of heart failure, and a systematic approach to collection of the contemporary data vital for patient-centered decision-making. She is currently serving as co-chair for ACC committees on the inpatient HF pathway and incorporation of patient-reported outcomes into cardiology practice.

Strong commitments for her remain training for the next generation to sustain the spirit of challenge, the patient-doctor relationship, and the synthesis of evidence to guide individualization of care for patients into alignment with their goals for quality and length of life.

Ralph Stephan von Bardeleben

Heart Center Mainz Cardiology I
Universitätsmedizin Mainz
Langenbeckstr. 1, 55131 Mainz
Stephan.von_Bardeleben@unimedizin-mainz.de
+49-(0)6131-17-2892/-6903

Current position

■ Senior Consulting Cardiologist, Heart Center Cardiology, University Medicine Universitätsmedizin , Mainz, Germany ■ Vize Head Structural and Valve Interventions, Head Mitral/Tricuspid Inverventions Head GUCH Adult Congenital Heart Disease ■ President German WG Echocardiography of the German Society of Cardiology Nucleus Valve Therapies AGIK WG Interventional Cardiology ■ Member ESC, EAPCI, EACVI, Faculty ACC, EuroPCR, TVT, TCT

Scientific background

3D Cardiac Imaging incl. Image Fusion
Imaging of Coronary Ischemia
CEUS Contrast Imaging
Interventional Valve Therapy and Imaging

Professional Career

■ 1988-1995: Medical Studies at the Johannes Gutenberg-Universität Mainz and UCSF Medical School San Franscisco (DAAD). Internal Medicine Ludwigshafen

■ 1995-2003: Internal Medicine, Intensive Care Medicine, Cardiology

■ 2004-2005: Interventional Cardiology

■ 2006-2011: Senior Consultant and Head of the Cardiovascular Imaging Labs. Certificate Grown Up Congenital Heart Disease incl.

■ 2010: Interventions Faculty EuroPCR,TCT, TVT, EAPCI, EACTS

■ 2014-2018: President WG Echocardiography of the German Soc. Of Cardiology Nucleus Valvular Heart Disease AGIK, Member EAPCI, EACVI

Stipendia/Honors

■ 1995: Zondek-Reward Charité, Berlin

■ 2003: EAE/ESC-Young Investigator Award Fin., ESC Cardiology

■ 2015: ESC Award Interventional Valve Therapy on TRAMI registry

Boards/Trials

■ Board Member: Nucleus DGIM, President Echocardiography German Soc. Of Cardiology

■ Faculty Mitgliedschaften: TCT, EAPCI, TVT, PCR, Akademie der DGK, EAPCI, EACVI, AGIK

■ Review: Review Journals wie CAIM, IJC, EHFJ, PCR Eurointervention, JACC CVI etc.

■ Trials: Bracco, Mailand, SonoVue BRA-013 Echo Corelab, Bracco Phönix-Trial als PI

Bracco Lumason local PI; Abbott Vascular RESHAPE 2 Steering com./ PI / Echo Corelab; Valtech Cardioband ce mark trial local PI. IIT RCT RESHAPE-HF PI. EnLigthn-Studie Renal Denervation, MATTERHORN , local PI und Echocorelab. Absorb IV-Studie, Sub-investigator; Apposition-V Studie; Steering Commitee FDA Pivotal Trial Cardiac Dimension Carillon (USA); Steering Committee RESHAPE-2 Trial (IIT Göttingen – Europa MCT); Steering Committee TRILUMINATE and eligibility commitee

TRI REPAIR ce mark local PI

Guidelines Forum
EMA REPRESENTATIVES

Giuseppe M.C. Rosano

MD, PhD
Consultant Cardiologist and Professor of Cardiology
St George's University Medical School, London, UK
Director of the Centre for Experimental and Clinical Pharmacology IRCCS
San Raffaele Rome, Italy
E-mail: grosano@sgul.ac.uk

MD in Medicine and Surgery at the La Sapienza University of Rome with full honors in 1988, Specialization in Cardiology in 1992
PhD in Medical Sciences from the Imperial College in London

He has authored over 400 peer-reviewed articles, 5 books and 28 book chapters.
He currently serves as an expert in the area of Cardiovascular Medicine for the European Assessment Office of the Italian Drug Agency (AIFA), he is core member of the Cardiovascular Working Party of the European Medicines Agency.

He is board member of the Heart Failure Association (HFA) and Nucleus member of the Working Group on Cardiovascular Pharmacotherapy of the ESC

Krishna Prasad

MB, BS, MD, FRCP, FF-FMLM
Group Manager, and Expert Assessor
MHRA, DoH, UK and St Thomas Hospital, London
Email; Krishna.Prasad@mhra.gov.uk

Krishna Prasad is a Group Manager at the UK Regulatory Agency with direct management responsibility for 3 therapy areas (Cardiovascular-Diabetes, Anti-infectives and Oncology) and an Honorary Cardiologist at St. Thomas' hospital, London. He has worked for MHRA, the UK regulatory agency over 15 years initially as reviewer progressing to lead the cardio-renal-diabetes areas and subsequently to the current post. His areas of special interest in cardiology are heart failure, CV risk factors, arrhythmias, cardiomyopathies and sudden death. He is a long-standing member of European Society of Cardiology. He has a keen interest in clinical trials, trial methodology and CV endpoints for outcome trials and biomarkers. His experience includes review of renal toxicity biomarkers, applications for renal diseases and CV outcomes in renal disease patients. Krishna is a regular participant in the regulatory roundtable dialogues with European Society of Cardiology and European Heart Failure association.

An active member of two different EMA/CHMP working groups- cardiovascular-Diabetes WP (2008) and the Pharmacogenomics WP (2005), he has coordinated several regulatory guidelines in these areas. He is an author and rapporteur for several EMA/CHMP guidelines in CV area including the heart failure guidelines, lipid lowering agents, and has lead the European efforts in harmonising the ICH E14 guideline including the Q and As.

Keenly interested in developing proportionate regulation and advances in regulatory science, he is the joint lead on the agency's Personalised Medicine strategy. He is an active participant in the UK and European regulatory initiatives in these areas. An active participant and proponent of many of the regulatory-scientific dialogues across the globe, he has a keen interest in harmonisation of approaches to both clinical trials and regulatory guidance development.

TRANSLATIONAL MEDICINE ACADEMY

ORGANISATION

The Heart Failure Guidelines Forum is organized by the Translational Medicine Academy.

Contact us

TMA Foundation
Email: info@tmacademy.org
Charles Schoen
William Melhuish / Yann Colardelle
Tel.: + 33 (0) 6 16 54 81 57
E-mail: william@mededgs.com and yanncol@tmacademy.org

www.tmacademy.org